Reporting Suspected or Actual Violations Sample Clauses

Reporting Suspected or Actual Violations. Business Associates, and those acting on their behalf in connection with work for Pfizer, are expected to raise concerns related to potential violations of these International Anti-Bribery and Anti-Corruption Principles or the law. Such reports can be made to a Business Associate’s primary point of contact at Pfizer, or if a Business Associate prefers, to Pfizer’s Compliance Group by e-mail at xxxxxxxxx.xxxxxxxxxx@xxxxxx.xxx or by phone at 0-000-000-0000.
Sample 1Sample 2Sample 3See All (12)
AutoNDA by SimpleDocs
Reporting Suspected or Actual Violations. Business Associates, and those acting on their behalf in connection with work for Pfizer, are expected to raise concerns related to potential violations of these International Anti-Bribery and Anti-Corruption Principles or the law. Such reports can be made to a Business Associate’s primary point of contact at Pfizer, or if a Business Associate prefers, to Pfizer’s Compliance Group by e- mail at xxxxxxxxx.xxxxxxxxxx@xxxxxx.xxx or by phone at +0-000-000-0000. Individuals employed from the following Government Bodies with which Pfizer commonly interacts are automatically considered GOs in Canada:
Sample 1Sample 2Sample 3See All (4)
Reporting Suspected or Actual Violations. Business Associates, and those acting on their behalf in connection with work for Pfizer, are expected to raise concerns related to potential violations of these International Anti-Bribery and Anti-Corruption Principles or the law. Such reports can be made to a Business Associate’s primary point of contact at Pfizer, or if an Associate prefers, to Pfizer’s Compliance Group by e-mail at xxxxxxxxx.xxxxxxxxxx@xxxxxx.xxx or by phone at 0-000-000-0000. Schedule FCPA1 - Government Bodies with which Pfizer Commonly Interacts • Health Canada • Industry Canada • Privy Council Office • Prime Minister's Office • Foreign Affairs and International Trade • Patented Medicine Prices Review Board • Veterans Affairs Canada • National Defence • Finance Canada • Royal Canadian Mounted Police • Common Drug Review (CDR) • Canadian Agency for Drugs and Technologies in Health (CADTH) • Integrated Health Agencies (Atlantic Canada) Examples of Government Officials Include: • Elected or appointed Government Officials; • Public servants; • Réseaux locaux de services de santé et de services sociaux (CSSS - successor to CLSCs) (Québec) • Groupes de médecine familiale (Québec) • Cliniques réseau (CR or CMA) (Québec) • Local Health Integration Network (Ontario) • Family Health Teams (Ontario) • Regional Health Authorities (Western Canada) • Canadian Food Inspection Agency • Veterinary Drugs Directorate • Aquaculture Canada • Declared political candidates (whether for party nomination or election); • HCPs who meet the criteria set forth in the definition of Government Official, e.g., HCPs employed by (a) the military, (b) the Correctional Service of Canada (prisons and penitentiaries), or (c) government operated or controlled hospitals or institutions (e.g., mental institutions, veterans affairs hospitals) and HCPs serving on government task forces or committees (e.g., Management of Severe Pain Advisory Committee of Experts, AIDS Advisory Committee, National Advisory Council on Aging, Medical Advisors Group); • HCPs that are officers / directors of, employed by or affiliated with, any publicly funded health care institution (e.g. hospital, clinic etc.) or institute of higher learning (e.g. college, CEGEP, university etc.); • Officers, employees or individuals who act in an official capacity on behalf of the United Nations, World Health Organization, World Trade Organization, International Joint Commission – United States and Canada, International Committee of the Red Cross, North American...
Sample 1
Reporting Suspected or Actual Violations. Business Associates, and those acting on their behalf in connection with work for Pfizer, are expected to raise concerns related to potential violations of these International Anti-Bribery and AntiCorruption Principles or the law. Such reports can be made to a Business Associate's primary point of contact at Pfizer, or if a Business Associate prefers, to Pfizer's Compliance Group by email at corporate. xxxxxxxxxx@xxxxxx.xxx or by phone at 1-212- 000-0000. Za Obdarovaneho / For the Beneficiary: Ona/ Date: Name/ Meno a priezvisko: prof. MUDr. Juraj Šteňo, DrSc. Podpis / Signature: ani nepriamo vykonávať, sľubovať alebo schvaľovať' vykonanie korupčnej platby, ani poskytnúť čokoľvek cenne akejkoľvek osobe s cieľom primäť poskytnúť' nezákonnú obchodnú výhodu spoločnosti Pfizer.  Obchodní partneri a osoby jednajúce v ich mene v spojení s pracou pre spoločnosť Pfizer nesmú priamo ani nepriamo vyžadovať', súhlasiť' s prijatím alebo prijať platbu alebo čokoľvek hodnotne ako nepatričnú ponuku v spojení s obchodnou činnostnou pre spoločnosť' Pfizer.  Zamestnanci spoločnosti Pfizer majú zakázané od obchodných partnerov a osôb jednajúcich v ich mene v spojení s pracou pre spoločnosť' Pfizer prijímať' dary, služby, výhody, zábavu alebo iné položky väčšie ako symbolické alebo zanedbateľné peňažné hodnoty. Okrem toho sú dary zanedbateľnej hodnoty povolene iba pokiaľ sú prijímane len občas a pri vhodných príležitostiach. Ohlasovanie porušenia alebo podozrenia na porušenie obchodní partneri a osoby jednajúce v ich mene v spojení s pracou pre spoločnosť' Pfizer majú povinnosť' ohlásiť' podozrenie na potenciálne porušenie týchto medzinárodných zásad proti úplatkárstvu a korupcii alebo zákona. Hlásenie je možné poslať' primárnej kontaktnej osobe obchodného partnera v spoločnosti Pfizer alebo e-mailom na adresu: corporate. compliance@pfizer. com, pripadne telefonicky na čísle 1-212- 733-3026. Za Obdarovaného / For the Beneficiary: Ona/ Date: Name/ Meno a priezvisko: prof. MUDr. Juraj Šteno, DrSc.
Sample 1
Reporting Suspected or Actual Violations. In conducting Pfizer-related activities, Business Associates, and those acting on behalf in connection with work for Pfizer, are expected to raise concerns related to potential violations of these International Anti-Bribery and Anti-Corruption Principles or the law. Such reports can be made to a Business Associate’s primary point of contact at Pfizer, or if an Associate prefers, to Pfizer’s Compliance Group, by e-mail at xxxxxxxxx.xxxxxxxxxx@xxxxxx.xxx or by phone at 0-000-000-0000. Schedule 1.14 Compounds [*****] [End of Schedule 1.14] [*****] Certain identified information denoted with an asterisk have been omitted from this exhibit because it is not materia l and would likely cause competitive harm to the Registrant if publicly disclosed. Schedule 3.4.1 Marginal Royalty Rate Calculation Example By way of example only, if Net Sales by Pfizer, its Affiliates or its Sublicensees in the Territory during a Pfizer Year are $3.2 billion, then the royalties payable by Pfizer under Section 3.4.1 during such Pfizer Year would be calculated as follows: Royalty payable for applicable Pfizer Year [*****] [*****] Certain identified information denoted with an asterisk have been omitted from this exhibit because it is not material and would likely cause competitive harm to the Registrant if publicly disclosed. Schedule 2.6 Technology Transfer [*****] [*****] Certain identified information denoted with an asterisk have been omitted from this exhibit because it is not material and would likely cause competitive harm to the Registrant if publicly disclosed. Schedule 6.4.1 Theravance Press Release [attached] [*****] Certain identified information denoted with an asterisk have been omitted from this exhibit because it is not material and would likely cause competitive harm to the Registrant if publicly disclosed. Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program Topically-Applied, Skin-Selective Pan-JAK Inhibitors Specifically Designed to Target Pro-Inflammatory Pathways with Minimal Systemic Exposure DUBLIN, IRELAND AND NEW YORK – December 23, 2019 – Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma”) and Pfizer Inc. (NYSE: PFE) (“Pfizer”) today announced that the companies have entered into a global license agreement for Theravance Biopharma’s preclinical program for skin-targeted, locally-acting pan-Janus kinas...
Sample 1
Reporting Suspected or Actual Violations. Business Associates, and those acting on their behalf in connection with work for XXX, are expected to raise concerns related to potential violations of these International Anti-Bribery and Anti-Corruption Principles or the law. Such reports can be made to a Business Associate’s primary point of contact at XXX, or if a Business Associate prefers, to XXX’s Compliance Group by e-mail at XXXX or by phone at XXXX. Attachment C EQUIPMENT AND MATERIALS NOT APPLICABLE Attachment D PROTECTION OF PERSONAL DATA
Sample 1
Reporting Suspected or Actual Violations. Business Associates, and those acting on their behalf in connection with work for Pfizer, are expected to raise concerns related to potential violations of these International Anti-Bribery and Anti-Corruption Principles or the law. Such reports can be made to a Business Associate’s primary point of contact at Pfizer, or if a Business Associate prefers, to Pfizer’s Compliance Group by e-mail at xxxxxxxxx.xxxxxxxxxx@xxxxxx.xxx or by phone at 0-000-000-0000. Provision of Services (the “Terms and Conditions”) Page: 8 of 8 SCHEDULE B ANNUAL COMPLIANCE CERTIFICATE We, the Supplier hereby certify:
Sample 1
AutoNDA by SimpleDocs
Reporting Suspected or Actual Violations. Business Associates, and those acting on their behalf in connection with work for Xxxxxx, are expected to raise concerns related to potential violations of these International Anti-Bribery and Anti-Corruption Principles or the law. Such reports can be made to a Business Associate’s primary point of contact at Upjohn, or if a Business Associate prefers, to Xxxxxx’s Compliance Group by e-mail at xxxxxxxxx.xxxxxxxxxx@xxxxxx.xxx or by phone at +0-000-000-0000. Individuals employed from the following Government Bodies with which Upjohn commonly interacts are automatically considered GOs in Canada:
Sample 1

Related to Reporting Suspected or Actual Violations

  • Reporting Violations a) When appropriate, faculty members will submit timely written communication to their immediate supervisor any condition that comes to their attention that may, in their judgment, pose a threat to the health or safety of any person associated with the District.

  • WAGE VIOLATIONS Contractor represents and warrants that, during the term of this Master Contract and the three (3) year period immediately preceding the award of the Master Contract, it is not determined, by a final and binding citation and notice of assessment issued by the Washington Department of Labor and Industries or through a civil judgment entered by a court of limited or general jurisdiction, to be in willful violation of any provision of Washington state wage laws set forth in RCW chapters 49.46, 49.48, or 49.52.

  • No Undisclosed Events, Liabilities, Developments or Circumstances No event, liability, development or circumstance has occurred or exists, or is reasonably expected to exist or occur with respect to the Company, any of its Subsidiaries or any of their respective businesses, properties, liabilities, prospects, operations (including results thereof) or condition (financial or otherwise), that (i) would be required to be disclosed by the Company under applicable securities laws on a registration statement on Form S-1 filed with the SEC relating to an issuance and sale by the Company of its Common Stock and which has not been publicly announced, (ii) could have a material adverse effect on any Buyer’s investment hereunder or (iii) could have a Material Adverse Effect.

  • No Violation of Environmental Laws There is no pending action or proceeding directly involving the Mortgaged Property in which compliance with any environmental law, rule or regulation is an issue; there is no violation of any environmental law, rule or regulation with respect to the Mortgaged Property; and nothing further remains to be done to satisfy in full all requirements of each such law, rule or regulation constituting a prerequisite to use and enjoyment of said property;

  • Repeat Violations Xxxxxx agrees to comply with all regulatory requirements and acknowledges that repeat violations could result in increased penalties in the future.

  • Convicted, Discriminatory, Antitrust Violator, and Suspended Vendor Lists In accordance with sections 287.133, 287.134, and 287.137, F.S., the Contractor is hereby informed of the provisions of sections 287.133(2)(a), 287.134(2)(a), and 287.137(2)(a), F.S. For purposes of this Contract, a person or affiliate who is on the Convicted Vendor List, the Discriminatory Vendor List, or the Antitrust Violator Vendor List may not perform work as a contractor, supplier, subcontractor, or consultant under the Contract. The Contractor must notify the Department if it or any of its suppliers, subcontractors, or consultants have been placed on the Convicted Vendor List, the Discriminatory Vendor List, or the Antitrust Violator Vendor List during the term of the Contract. In accordance with section 287.1351, F.S., a vendor placed on the Suspended Vendor List may not enter into or renew a contract to provide any goods or services to an agency after its placement on the Suspended Vendor List. A firm or individual placed on the Suspended Vendor List pursuant to section 287.1351, F.S., the Convicted Vendor List pursuant to section 287.133, F.S., the Antitrust Violator Vendor List pursuant to section 287.137, F.S., or the Discriminatory Vendor List pursuant to section 287.134, F.S., is immediately disqualified from Contract eligibility.

  • Material Changes; Undisclosed Events, Liabilities or Developments Since the date of the latest audited financial statements included within the SEC Reports, except as set forth on Schedule 3.1(i), (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth on Schedule 3.1(i), no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.

  • Reports of unusual occurrence The Contractor shall, during the Maintenance Period, prior to the close of each day, send to the Authority and the Authority’s Engineer, by facsimile or e- mail, a report stating accidents and unusual occurrences on the Project Highway relating to the safety and security of the Users and Project Highway. A monthly summary of such reports shall also be sent within 3 (three) business days of the closing of month. For the purposes of this Clause 15.4, accidents and unusual occurrences on the Project Highway shall include:

  • Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting The Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act), which (i) are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company’s principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared; (ii) have been evaluated by management of the Company for effectiveness as of the end of the Company’s most recent fiscal quarter; and (iii) are effective in all material respects to perform the functions for which they were established. Since the end of the Company’s most recent audited fiscal year, there have been no significant deficiencies or material weakness in the Company’s internal control over financial reporting (whether or not remediated) and no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

  • Non-Violation Section 1. It shall not be a violation of this Agreement, if an Employee or Employees cease work because of:

Time is Money Join Law Insider Premium to draft better contracts faster.